Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent... As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
- Mechanism
- Curator reviewed
Marimastat is a broad spectrum matrix metalloprotease inhibitor. It mimics the peptide structure of natural MMP substrates and binds to matrix metalloproteases, thereby preventing the degradation of the basement membrane by these proteases. This antiprotease action prevents the migration of endothelial cells needed to form new blood vessels. Inhibition of MMPs also prevents the entry and exit of tumor cells into existing blood cells, thereby preventing metastasis.
- Primary indication
- For the treatment of various cancersCurator reviewed
- Formula / weight
- C15H29N3O5 · 331.4079 g/mol (avg)
- Code names
- BB-2516 · GI-5712 · KB-R 8898 · TA-2516
Resolves to
OCSMOTCMPXTDND-OUAUKWLOSA-NSMILESCNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO)C(C)(C)CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Marimastat, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account